INTRODUCTION {#sec1}
============

Personalized medicine (PM)^[1](#fn1){ref-type="fn"}^ aims to harness a wave of 'omics'^[2](#fn2){ref-type="fn"}^ discoveries to tailor drug choices, dosages, and interventions to the biology of individual patients. Its goals are to target better healthcare, facilitate research and discovery of diagnostics and therapies, and predict individual predispositions to diseases or conditions.^[3](#fn3){ref-type="fn"}^ The Precision Medicine Initiative (PMI),^[4](#fn4){ref-type="fn"}^ announced by President Obama in January 2015 to 'enable a new era of medicine through research, technology and policies that empower patients researchers and providers to work together toward development of individualized care', fits within this broad definition of PM. The term precision medicine, however, is more mechanistic: its goal is to integrate individual-level molecular and clinical data to develop a more accurate taxonomy of diseases to enhance diagnosis, treatment, and disease management.^[5](#fn5){ref-type="fn"}^

The promise of PM is both therapeutic and economic. Many countries have invested financial, human, and infrastructure resources into the development and delivery of PM, hoping to provide better, more individualized healthcare and to use healthcare dollars more efficiently. High-throughput sequencing and bioinformatics infrastructure are facilitating PM research and development (R&D). However, while infrastructure costs are rapidly decreasing, human capacity to interpret and clinically apply 'omics' results remains a costly barrier to the widespread implementation of PM.^[6](#fn6){ref-type="fn"}^

A further goal of PM is to reinvigorate stagnating therapeutic R&D.^[7](#fn7){ref-type="fn"}^ Despite substantial increases in R&D investments to US\$50 billion per year, the number of new drugs approved annually in the USA has remained constant over the past 60 years.^[8](#fn8){ref-type="fn"}^ The high cost of many new therapies is in part driven by the cost of failures in clinical development: only 15.3% of drugs traverse the pipeline from phase I to market authorization for lead indications, a percentage that drops to 10.4% for all indications.^[9](#fn9){ref-type="fn"}^ The greatest rate of failure occurs due to a lack of evidence of efficacy in phase II. Specifically, for cancer R&D, a key target for PM, billions of dollars of investment have produced median gains in progression-free survival of only 2.1 months and median gains in overall survival of only 2.5 months for new cancer drugs developed between 2002 and 2014.^[10](#fn10){ref-type="fn"}^ PM promises to improve the current R&D environment with a more targeted approach. It will refine our understanding of disease taxonomy and thereby enable us to design clinical trials that enroll participants more likely to benefit from experimental interventions. This promises to improve efficacy and thus decrease clinical trial failure rates.

Despite significant investment, limited progress has been made to date in bringing PM products to the market.^[11](#fn11){ref-type="fn"}^ While there have been some successes in precision medicine, notably in the field of oncology, its products are not currently in use for most diseases.^[12](#fn12){ref-type="fn"}^ Challenges to progress in PM are both scientific and non-scientific. This paper focuses on the latter: we detail the major perceived non-science barriers to the creation, translation, and introduction of PM products into clinical care. We focus especially on those challenges that exist in the regulatory approvals arena, such as clinical trial design, the legal environment that impacts incentives for PM R&D, and the regulations that impact reimbursement of medical therapies, for example, a requirement for evidence of clinical utility. Despite harmonized rules for regular pharmaceutical clinical trials in the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH),^[13](#fn13){ref-type="fn"}^ a significant challenge to the international adoption of PM products is a lack of internationally accepted best practice standards, coupled with a lack of clear evidentiary standards for regulatory approval or reimbursement (in health insurance schemes). Existing standards are not harmonized across jurisdictions to facilitate cross-border movement or adoption of PM products. In large part, this reflects the confusion or inadequacy of regulatory and practice standards for PM within national borders.

Even though our research was international in scope, in this paper we focus on regulation of PM in the USA. This focus reflects the dominance in medical research with respect to funding and volume in that country. For example, President Obama\'s ambitious PMI includes the PMI Cohort Program, renamed under the current administration to All of Us, which will collect health and biospecimen data from over a million volunteers to facilitate research on individual variations in genetics, lifestyle, and environment. This research should facilitate delivery on the promise of PM. Furthermore, developments in the USA influence global norms for human subjects research through the ICH; and most PM products will seek approvals from the US Federal Drug Administration (FDA).^[14](#fn14){ref-type="fn"}^ Finally, there is considerable political will^[15](#fn15){ref-type="fn"}^ to create regulatory and policy incentives, including regulatory pathways to facilitate the introduction of PM products into American healthcare markets.

RESEARCH QUESTION AND METHODS {#sec2}
=============================

We used a scoping review to answer the following research questions: (i) What are the primary legal and regulatory challenges for the development and implementation of PM identified in the academic literature? and (ii) What solutions have been proposed in the academic literature to address these challenges? A scoping review provides a systematic overview of the type, extent, and quantity (but not the quality) of literature in a given research field.^[16](#fn16){ref-type="fn"}^ It also provides a mechanism to summarize and disseminate research findings to policy makers, practitioners, and consumers. We adapted the *Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement*^[17](#fn17){ref-type="fn"}^ to report the flow of information through the different phases of our scoping review (Figure [1](#fig1){ref-type="fig"}).

![PRISMA diagram of personalized medicine scoping review method, illustrating inclusion/exclusion criteria. Adapted from Moher et al.^17^](lsx030fig1){#fig1}

We defined PM as seeking 'to improve stratification and timing of healthcare by utilizing biological information and biomarkers on the level of molecular disease pathways, genetics, proteomics as well as metabolomics'.^[18](#fn18){ref-type="fn"}^ We defined barrier as a regulatory structure identified by the study author as an impediment to PM development. We identified recommendations by looking for 'ought' statements about how regulatory systems could facilitate PM development. Based on this vocabulary and a list of synonyms for PM, developed with the input of a research librarian, we searched PubMed, Scopus, and LexisNexis for papers published between January 1, 2010 and April 1, 2014 (see Appendix). On September 30, 2014, the FDA published draft guidelines on a laboratory developed test (LDT) regulatory oversight framework. By then, LDT regulation had emerged as a topic of interest in our analysis. To capture responses to the proposed guidelines in the literature, we therefore extended our search period until February 6, 2015. For logistical reasons, we only conducted the extended search in PubMed. We imported all search results into Endnote 7 and removed duplicates. Of 5304 articles identified by our initial searches, 3057 remained. In consultation with economic and legal experts, we developed inclusion and exclusion standards to apply to our search results. We included English language papers that addressed both our definition of PM and regulatory challenges/barriers to PM development or proposed solutions to regulatory challenges/barriers to PM development. We included papers written on the regulatory systems affecting PM development in the European Union (EU), the USA, Canada, Japan, Singapore, and China.

Two researchers, WL and a research assistant, evaluated the titles and abstracts of search results for inclusion in the analysis. To ensure validity, the two researchers evaluated the same subset of titles and articles, and then compared their results. We calculated a kappa score, a standard measure for intercoder reliability, of \>0.9, indicating consistent application of the inclusion and exclusion criteria.^[19](#fn19){ref-type="fn"}^ Eight hundred and thirty articles met our inclusion criteria. We retrieved full texts versions of these 830 articles, and two researchers (WL and LK) re-applied the inclusion and exclusion criteria to the full papers. They independently reviewed the same papers, representing 10% of the total dataset, and met to compare findings. Discrepancies were resolved through discussion to consensus. The authors then independently reviewed the remaining 746 papers for inclusion in the study, resulting in 344 articles that met our inclusion criteria.

We used NVivo^10^, a qualitative analysis software package, to assign relevant text from these 344 articles to subthemes and to organize subthemes into main themes. We constructed separate categories for barriers and recommendations. Using an inductive approach, WL and LK based their initial subthemes on the article text. We then organized these subthemes into main themes that minimized redundancy and overlap without losing important nuance. WL and LK assigned text to subthemes and main themes based on consensus discussion. When new subthemes emerged, we re-checked already analysed articles to apply the new subthemes. This iterative process is known in qualitative research as the constant comparison method.^[20](#fn20){ref-type="fn"}^ We then summarized the features of the subthemes and main themes and provided these to experts in law and economics. We asked these experts to contextualize the barriers and recommended solutions we identified. This paper summarizes the themes for challenges and associated recommendations. Note that due to the time-consuming nature of a scoping review, we have added updated discussion of articles from targeted searches conducted after February 6, 2015.

OVERCOMING CHALLENGES FOR THE DEVELOPMENT AND IMPLEMENTATION OF PM {#sec3}
==================================================================

We identified eight main themes in our set of 344 articles related to challenges for the development and implementation of PM.^[21](#fn21){ref-type="fn"}^ These themes were unevenly represented across the literature set. Of the 344 articles, 40.1% discussed regulatory uncertainty; 25.3% discussed reimbursement; 20.1% discussed clinical trial regulations and design; 17.7% discussed regulations for co-development of pharmaceuticals and companion diagnostics (CDx); 16.0% discussed conflicting and unclear evidentiary standards in regulations; 14.0% discussed lack of or ineffective legal incentives for PM R&D; 12.5% discussed problematic or incompatible information systems and privacy concerns; and 11.3% discussed regulation of LDTs and direct-to-consumer (DTC) genetic tests. Table [1](#tbl1){ref-type="table"} lists the acronyms used in our discussion.

###### 

List of acronyms.

  Acronym   Term
  --------- -----------------------------------------------------------------------------------------------------------------------
  CDx       Companion diagnostics
  CER       Comparative effectiveness research
  CLIA      Clinical Laboratories Improvement Amendments
  CMS       Center for Medicare and Medicaid Services
  DTC       Direct to consumer
  EHR       Electronic health records
  EU        European Union
  FDA       Food and Drug Administration
  FTC       Federal Trade Commission
  GINA      Genetic Information Non-Discrimination Act
  HIPAA     Health Insurance Portability and Accountability Act
  HTA       Health technology assessment
  ICH       International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
  IND       Investigational New Drug Application
  IRB       Institutional review board
  LDT       Laboratory developed test
  NIH       National Institutes of Health
  ODA       Orphan Drug Act
  PHI       Protected health information
  PM        Personalized medicine
  PMA       Premarket approval
  PMI       Personalized Medicine Initiative
  PMR       Postmarket research studies
  R&D       Research and development
  RCT       Randomized controlled trial
  SAE       Serious adverse events
  SSRD      Single subject research design
  USA       United States of America

Regulatory uncertainty was the most discussed challenge for PM R&D and implementation. This was not surprising given that governments and healthcare systems were developing new regulations, guidance documents, and regulatory initiatives for PM. Because regulatory uncertainty was a cross-cutting theme, we discuss it in the context of each of the other themes, rather than in a stand-alone section. However, the key issue was that existing regulations appeared to be inapplicable to PM and suffered from a lack of harmonization, and thus interfered with PM development. Regulatory reform, whether to facilitate PM or to ensure greater safety and harmonization, created a climate of uncertainty, which created difficulties for research and approvals. There was a shared view that regulations were in flux, both in terms of frequent changes during the life cycle of drug or diagnostic development, and in terms of the flexibility with which those regulations might be applied for different PM products and services. For some stakeholders, changes to regulations were occurring too quickly,^[22](#fn22){ref-type="fn"}^ while for others a lack of clarity and transparency in applicable regulations created uncertainty.^[23](#fn23){ref-type="fn"}^

An exemplar of regulatory reform that generated uncertainty in PM R&D and implementation is the 21st Century Cures Act^[24](#fn24){ref-type="fn"}^ (the Act), passed by US Congress on December 7, 2016, and which President Obama signed into effect on December 13, 2016. The sweeping bipartisan legislation was widely supported by pharmaceutical industry and medical device manufacturers but was opposed by many consumer protection and patient safety groups.^[25](#fn25){ref-type="fn"}^ The act provides increased funding of nearly 5 billion dollars for biomedical research through the NIH, the PMI, the BRAIN initiative (research into the human brain), and cancer research (referred to as the Cancer Moonshot).^[26](#fn26){ref-type="fn"}^ Further, the act provides states with funding for opioid abuse prevention and funding at the federal level for increased research on and prevention of mental illness.^[27](#fn27){ref-type="fn"}^

Central to the act\'s aim of facilitating the adoption of new therapies are controversial provisions that provide incentives for experimental therapies and faster and easier approvals for innovative drugs and medical devices.^[28](#fn28){ref-type="fn"}^ In particular, the use of patient experience data and 'real-world evidence' (including clinical experience data) in the approvals process, in addition to the standard data from randomized clinical trials, has raised concerns.^[29](#fn29){ref-type="fn"}^ Primary among these concerns is that the loosening of evidentiary requirements for FDA approval will come at the cost of patient safety.^[30](#fn30){ref-type="fn"}^

The act also facilitates a review pathway for biomarkers and other tools (such as animal model research) that help facilitate the development of new drugs.^[31](#fn31){ref-type="fn"}^ It provides regulatory clarity on the best path for approvals of combination products.^[32](#fn32){ref-type="fn"}^ The FDA has been directed to publish guidance on novel or adaptive clinical trial designs to ease burdens on companies submitting applications for approvals.^[33](#fn33){ref-type="fn"}^

The ripple effects of broader regulatory changes also generate uncertainty for PM R&D and implementation by compounding the effects of other regulatory changes. Under the current administration of President Trump, the implementation of the 21st Century Cures Act faces uncertainty given both a hiring freeze for federal employees that will make it difficult for the FDA to hire the technicians and staff necessary to undertake the work of the act.^[34](#fn34){ref-type="fn"}^ Additionally, in an effort to eliminate much of the federal regulatory bureaucracy, President Trump signed an executive order requiring the elimination of two regulations for each new regulation passed.^[35](#fn35){ref-type="fn"}^ The order also applies to federal guidances of the kind used by the FDA to explain how companies can meet the requirements of the agency. To implement the act, the FDA would have to pass a number of regulations and publish several guidances. It remains unclear, therefore, whether President Trump will exempt the FDA from the executive order so that it can implement the act.

Further, the Trump administration has proposed cutting the budget of the NIH by approximately 18%, which puts in jeopardy research programs such as the Cancer Research Moonshot, and substance abuse (opioid abuse) programs.^[36](#fn36){ref-type="fn"}^ In addition, the majority of the spending in the act was to have come from the Prevention and Public Health Fund, created under the Affordable Care Act (ACA).^[37](#fn37){ref-type="fn"}^ With legislation proposed to repeal the ACA before the Senate at the time of writing, ^[38](#fn38){ref-type="fn"}^ it is unclear what impact such a repeal might have on the implementation of the act. What is clear is that both funding and implementation of the FDA initiatives and other biomedical research programs of the 21st Century Cures Act face increased uncertainty and delays in implementation.

In an environment of significant regulatory change, regulatory uncertainty is a barrier to realizing the potential of PM. PM developers weigh the risks posed by regulatory uncertainty when investing in PM R&D. And regulatory uncertainty hinders the implementation of PM, delaying potential benefits of PM to patients and healthcare systems. Specific recommendations for creating certainty and clarity in specific regulatory areas are embedded in the sections below.

Challenge: Clinical Trials {#sec3-1}
--------------------------

Randomized controlled trials (RCTs) provide the evidentiary gold standard of safety and efficacy required for regulatory approvals in most jurisdictions, with some exceptions for rare diseases.^[39](#fn39){ref-type="fn"}^ While differences exist, jurisdictions such as the USA, EU,^[40](#fn40){ref-type="fn"}^ and Canada^[41](#fn41){ref-type="fn"}^ require similar evidence of safety and efficacy to satisfy regulators. While clinical trials are necessary to ensure patient safety, numerous commentators posited that they created a significant barrier to the timely and efficient translation of research to therapy,^[42](#fn42){ref-type="fn"}^ especially in the area of PM. There is a profound tension between the goals of PM to provide stratified, smaller populations of patients with tailored therapies and standard clinical trial designs, which examine efficacy in a large segment of the generalizable patient population.^[43](#fn43){ref-type="fn"}^

Some concerns about clinical trials in the context of PM echoed general concerns about the regulation of clinical trials expressed by R&D firms in pharmaceutical and biotechnology sectors, researchers, and patient organizations. These concerns related to the long timelines (10--15 years) and high costs of clinical trials (\$2.87 billion dollars (in 2013 dollars)).^[44](#fn44){ref-type="fn"}^ These debates highlighted tensions between the regulatory process, which legislatively mandated regulators to approve only safe and efficacious products, and the interests of R&D firms and patients, which wished to bring potential therapies to market quickly and at lower cost. In the following sections, we expand on the PM subthemes in the 69 articles that discussed clinical trials, namely expense and delay (21 articles); uncertainties in the approvals process (13 articles); the use of biomarkers in clinical trials (17 articles); and clinical trial design (26 articles).

### Expense and Delay {#sec3-1-1}

Twenty-one articles discussed the time and expense required to generate both the preclinical and clinical data for FDA approval in the USA.^[45](#fn45){ref-type="fn"}^ Regulatory requirements drive up R&D costs, which are then reflected in the cost of approved therapeutics.^[46](#fn46){ref-type="fn"}^ Where market size is reduced due to stratification of patients into small populations likely to benefit from a given therapy, the additional cost of running a clinical trial may create a financial disincentive. The high cost of clinical trials can also create barriers to physician and patient uptake in the form of higher prices, and difficulties with downstream reimbursement, for the same aforementioned reason.^[47](#fn47){ref-type="fn"}^

### Biomarkers {#sec3-1-2}

A major impediment for PM developers is the high cost and complexity of establishing and validating predictive biological markers (biomarkers). Biomarkers are objectively measurable biological characteristics, including genetic variants, or medical signs that indicate a pathogenic process or pharmacological response to a particular therapy.^[48](#fn48){ref-type="fn"}^ Biomarkers may answer the following questions: 'Does the drug reach the target? Does it have the desired biological effect? Does it have an influence on other expected or unexpected targets? Does the drug affect characteristics that predict desired or undesired effects?'^[49](#fn49){ref-type="fn"}^ The presence or absence of a biomarker may predict whether and how a particular patient or subset of patients will respond to an experimental drug. Genetic biomarkers are particularly useful because genetic factors account for 15% to 30% of differences in drug metabolism and response between individuals.^[50](#fn50){ref-type="fn"}^ Pharmacogenetic tests use genetic variations between individuals to determine drug absorption and disposition, or drug activity.^[51](#fn51){ref-type="fn"}^ The ability to predetermine, with the use of biomarkers, the targeted patient population and therapeutic dosage should shorten drug development timelines, reduce expenses and provide a greater likelihood of bringing a drug successfully through the regulatory process. The development of appropriate biomarkers is therefore a major strategy for reinvigorating a lagging pharmaceutical business model focused on the development of blockbuster drugs that can be used in large portions of the population.^[52](#fn52){ref-type="fn"}^

There are, however, problems with the identification and the validation of biomarkers that have undermined their utility thus far. First, scientifically identifying and establishing biomarkers is difficult.^[53](#fn53){ref-type="fn"}^ Second, the regulatory criteria necessary to validate biomarkers are neither agreed upon nor clear. Third, there are difficulties in collecting high-quality data to show that the biomarker is clinically valid and useful, as biomarkers are often identified late in the drug development process when it becomes apparent that only a small subset of the patient population is reacting to the drug under development.^[54](#fn54){ref-type="fn"}^ Indeed, PM has the potential to 'rescue' a drug that has failed to perform as expected in clinical trials by using a biomarker to identify the subset population in which the drug is effective. This 'rebrands' the drug as a PM for patients with that biomarker;^[55](#fn55){ref-type="fn"}^ however, in this situation, where further investigation determines what biological or genetic factor is at work in the responding subpopulation, the drug is normally well along the drug validation and clinical development pipeline. Consequently, due to issues of timing, and difficulty generating adequate evidence, regulatory demands for biomarker validation data can often be greater than the evidence that emerges from the trials involving the biomarkers.

In the context of genetic biomarkers, differences exist between the evidentiary standards that are required to use a genetic test for a biomarker in a laboratory setting and those required by regulators before that test can be used in a clinical setting. Internal laboratory biomarker tests do not require independent validation and vary considerably from laboratory to laboratory and from jurisdiction to jurisdiction.^[56](#fn56){ref-type="fn"}^ Regulatory standards for the use of biomarkers in a clinical setting are generally higher, requiring analytical validation that can be difficult to provide to the FDA without prior planning and early identification.^[57](#fn57){ref-type="fn"}^

Finally, while PM developers see the opportunity to further reduce clinical trial sizes by identifying biomarker-positive participants, regulators are concerned with the risks posed to biomarker-negative patients. Regulators may therefore require both biomarker-positive and negative participants in clinical trials, thus reducing or nullifying any potential savings for the trial sponsor.^[58](#fn58){ref-type="fn"}^ While regulatory approval is still possible without this evidence, the approval will limit clinical application to biomarker-positive patients,^[59](#fn59){ref-type="fn"}^ unless physicians use it off-label.^[60](#fn60){ref-type="fn"}^ The manufacturer may further have to undertake postmarketing studies or phase IV clinical trials in biomarker-negative populations, which raises costs and uncertainty from a manufacturer\'s perspective.^[61](#fn61){ref-type="fn"}^

### Clinical Trial Design {#sec3-1-3}

Regulations require that clinical trials are designed with specific hypotheses and therapeutic targets in mind and proceed with prospective analysis to demonstrate safety and efficacy in a generalizable population. There are, therefore, significant tensions between standard clinical trial designs and designs adapted to the smaller patient subsets that are the hallmark of PM. First, smaller clinical trial designs provide inferior evidence of safety and efficacy due to the small numbers of patients involved.^[62](#fn62){ref-type="fn"}^ Small trials do not have the statistical power to detect efficacy, especially if the magnitude of the effect is predicted to be small. Second, without a large generalizable population study, it is difficult to fully understand the benefit/risk analysis of the drug.^[63](#fn63){ref-type="fn"}^ This is concerning because any off-label^[64](#fn64){ref-type="fn"}^ use by clinicians once the drug is approved can lead to unexpected and serious adverse events (SAE) not discovered in a phase III study. In addition, analysis of the subgroups enrolled in a clinical trial often comprises a retrospective analysis that takes place as the trial is ongoing or after a suboptimal or failed clinical trial.^[65](#fn65){ref-type="fn"}^ Such post hoc analysis requires a mid-stream course correction with new patient targets and a different hypothesis during or after the clinical trial to 'rescue' the drug candidate, and 'rebrand' it as a stratified therapeutic for a specific, smaller population.^[66](#fn66){ref-type="fn"}^ This type of post hoc analysis is not permitted under the current regulations, and it is not clear whether in all cases an entirely new clinical trial would be required.^[67](#fn67){ref-type="fn"}^

### Uncertainty in the Approval Process {#sec3-1-4}

In light of the preceding discussion, uncertainty about the clinical trial process for PM leads to uncertainty about the likelihood of regulatory approval. In addition to the high cost associated with the regulatory approval process, failure to gain approval means those costs cannot be recouped. Regulatory uncertainty in the clinical trial process exists with respect to the precise information companies must present to regulators for a successful application, and how that information will be used;^[68](#fn68){ref-type="fn"}^ the use of biomarkers;^[69](#fn69){ref-type="fn"}^ and the design of clinical trials that incorporate CDx.^[70](#fn70){ref-type="fn"}^ PM developers desire better guidance on how best to design a successful clinical trial for a personalized therapy, because absent guidance, they risk presenting suboptimal evidence regarding stratification options. Designing clinical trials for differently responding subgroups (for example, biomarker-positive and biomarker-negative groups) requires additional time and resources.^[71](#fn71){ref-type="fn"}^ Companies are reluctant to make this investment without a commensurate increase in the certainty of regulatory approval.

Meanwhile, regulators struggle to make evidence-based risk and benefit decisions from clinical trials with very small sample sizes, which do not capture rare SAE.^[72](#fn72){ref-type="fn"}^ While existing standards for clinical trial design may be suboptimal for PM,^[73](#fn73){ref-type="fn"}^ using novel clinical trial designs may not improve a therapeutic\'s chance for approval.^[74](#fn74){ref-type="fn"}^ In the absence of functional regulatory guidelines on clinical trial designs, PM developers and regulators will remain frustrated with the quality of evidence generated by clinical trials and the uncertain regulatory outcomes that follow.

Recommendations to Overcome Clinical Trial Challenges {#sec3-2}
-----------------------------------------------------

Given the numerous challenges posed by clinical trial regulations, many proponents of PM recommend changing or improving clinical trial design to aid PM development and clinical translation. In general, PM developers would like greater clarity and guidance about how information on biomarkers should be presented and how it will be used in the approvals process.^[75](#fn75){ref-type="fn"}^ Strengthening postmarket study and surveillance (PMR) requirements,^[76](#fn76){ref-type="fn"}^ using postmarketing authorization, encouraging phase IV clinical trials,^[77](#fn77){ref-type="fn"}^ gathering ongoing evidence^[78](#fn78){ref-type="fn"}^ and using limited or conditional approvals^[79](#fn79){ref-type="fn"},[80](#fn80){ref-type="fn"}^ are all frequently mentioned recommendations. Recommendations involving PMR include the creation of an 'approval with conditions'---a regulatory option that would fast track some approvals in combination with mandatory phase IV PMR and the creation of a centrally managed database for SAE reporting by physicians.^[81](#fn81){ref-type="fn"}^ It is thought that strengthening PMR could alleviate some of the difficulty companies have meeting evidentiary burdens, particularly with respect to bringing prospective population-segmented data to regulators.^[82](#fn82){ref-type="fn"}^ PMR might evaluate a drug\'s effect in a specific patient population or identify new uses for the drug.

Recommendations favoring mandatory PMR also reflect a general desire to capture SAE, and provide more rigorous feedback of clinical results into the regulatory process.^[83](#fn83){ref-type="fn"}^ PMR might be used to identify the variability that underlies serious event rates in different patient groups.^[84](#fn84){ref-type="fn"}^ To that end, recommendations range from using postmarking data collection pilot projects created by the Center for Medicare and Medicaid Services (CMS) and Centers for Disease Controls and Prevention as models for the FDA's Sentinel program,^[85](#fn85){ref-type="fn"}^ to standardizing reporting of SAE independent of pharmaceutical companies.^[86](#fn86){ref-type="fn"}^ This would foster greater transparency, learning, and quicker turnover of innovation, which, while desirable, is foreign to a strong trade secret and confidentiality ethos in medical product development. There is little consensus, however, on how mandatory PMR should be instituted, as an FDA power through legislation,^[87](#fn87){ref-type="fn"}^ or under a public/private funding partnership.^[88](#fn88){ref-type="fn"}^ The latter option leaves all information publicly owned and appears to be at odds with existing data protection laws. In addition, recommendations aim to mitigate the difficulties, both scientific and evidentiary, with the validation of biomarkers.^[89](#fn89){ref-type="fn"}^ Some propose the use of unvalidated biomarkers, so long as the sponsor commits to a phase IV clinical trial,^[90](#fn90){ref-type="fn"}^ or the use of biomarkers that emerge during the early phases of the trial.^[91](#fn91){ref-type="fn"}^

### Innovative Clinical Trial Design {#sec3-2-1}

Other recommendations relate to clinical trial design and several authors suggest a number of innovative or alternative trial designs to aid PM products through the regulatory approval stage. Several articles recommend that regulators work with PM manufacturers to create new models and provide greater guidance on permissible clinical trial design.^[92](#fn92){ref-type="fn"}^ Recommendations include innovations or alternatively designed studies that reduce costs,^[93](#fn93){ref-type="fn"}^ do not rely on animal models,^[94](#fn94){ref-type="fn"}^ or involve modified or conditional approval paired with a postapproval requirement to develop additional evidence.^[95](#fn95){ref-type="fn"}^ Adaptive trial design could reduce drug approval time and cost by recruiting only 'likely responders' based on biomarkers into clinical trials.^[96](#fn96){ref-type="fn"}^ Alternatively, adopting an 'adaptive group sequential design' involving rolling admissions of sensitive subgroups could overcome some of the current clinical trial design barriers.^[97](#fn97){ref-type="fn"}^

Authors also recommend regulatory acceptance of smaller clinical trial populations in lieu of prospective RCTs.^[98](#fn98){ref-type="fn"}^ Reliance on prospective-only trial design invalidates the use of retrospective analysis or identification of biomarkers during the course of clinical trials. Adaptive trial design that involves contemporaneous biomarker identification would overcome this regulatory barrier.^[99](#fn99){ref-type="fn"}^ Along with trial design that overcomes the difficulties with biomarker validation, several articles recommend moving from the traditional clinical trial group experimental design to Single Subject Research Design (SSRD) or 'N of 1' studies.^[100](#fn100){ref-type="fn"}^ This move would be difficult and controversial as SSRD studies are not sufficient to satisfy current clinical trial information and design for regulatory approval.^[101](#fn101){ref-type="fn"}^ Despite the difficulty, SSRD would help identify highly reactive patients and speed up evidence collection to meet regulatory requirements.^[102](#fn102){ref-type="fn"}^

Challenge: CDx and Co-Development {#sec3-3}
---------------------------------

A second challenge facing PM development is the significant uncertainty that exists around the optimal, possible, and acceptable clinical trial design for therapeutics intended to be used with CDx. This uncertainty negatively impacts the advantages predicted for PM in the combination of tailored therapies and diagnostics that identifies the optimal patient population. Such CDx, commonly regulated as medical devices, are most often in vitro assays^[103](#fn103){ref-type="fn"}^ or genetic tests. These assays and tests help identify the presence or absence of a biomarker, indicating the patient\'s suitability as the recipient of a particular therapy, such as a small-molecule drug, biologic, or gene/cell therapy. To fully exploit the therapeutic and economic advantages of the therapeutic--diagnostic partnership, ideally the CDx is marketed together and cross-labeled with its therapeutic to indicate paired use. Here, we expand on the subthemes related to co-development from 61 articles, namely issues with mandated co-development by regulators (32 articles); labeling issues (19 articles); lack of clarity on regulatory pathways (15 articles); the co-dependence of the therapeutic and the diagnostic threatens the success of both (8 articles); and the lack of appropriate business models for co-development (4 articles).

Regulatory preference to facilitate the pairing of a therapeutic and its CDx means that both should navigate the clinical trial and regulatory process at the same time. This will establish evidence that their use together is safe and effective. In a 2014 Guidance, the FDA indicated that co-development was preferred for CDx, including pharmacogenetic tests, ^[104](#fn104){ref-type="fn"}^ thereby making co-development all but mandated except for rare cases.^[105](#fn105){ref-type="fn"}^ The regulatory preference for co-development, as well as ongoing uncertainty about how to achieve this, is a significant barrier in PM development. Relatively few concurrently developed therapeutics and CDx exist to date.^[106](#fn106){ref-type="fn"}^

According to the FDA, a CDx should be identified and developed in parallel with a therapy. This is very difficult for developers, especially those in the private sector, to achieve, as R&D timelines for therapeutics and diagnostics do not support concurrent development.^[107](#fn107){ref-type="fn"}^ Since biomarkers that form the basis of most in vitro assays and tests are normally identified retrospectively and late in the therapy\'s validation process, ^[108](#fn108){ref-type="fn"}^ developers that identify useful CDx for a therapy after phase II clinical trials face regulatory challenges that increase time and cost of development.^[109](#fn109){ref-type="fn"}^ Additionally, achieving cooperation between different developers whose business interests may not be aligned is complicated and requires an unusual degree of transparency. Unlike large pharmaceutical developers, diagnostic developers are commonly small biotechnology companies that tend to have leaner business models and marketing budgets.^[110](#fn110){ref-type="fn"}^ These differences make full cooperation difficult.

Co-development may threaten the success of each company\'s product. Where the diagnostic is tied to the use of a particular drug, the success or failure of that drug in clinical trials determines the success or failure of the diagnostic.^[111](#fn111){ref-type="fn"}^ In situations in which the diagnostic might have multiple uses, co-development with a single drug may mean that the diagnostic will not clear regulatory hurdles for other uses. The converse occurs when rejection of the diagnostic leads to the rejection of the drug, which might otherwise be effective.^[112](#fn112){ref-type="fn"}^ Co-development can also delay the introduction of the drug or diagnostic while the other remains in the approval process. This can have profound economic consequences for both companies.^[113](#fn113){ref-type="fn"}^ Furthermore, pairing the use of a drug with a diagnostic may reduce market size for drug development companies.^[114](#fn114){ref-type="fn"}^ Finally, it is less complicated for a company to develop a stand-alone diagnostic.^[115](#fn115){ref-type="fn"}^ Thus, a myriad of disincentives contribute to the lack of co-developed drugs and diagnostics.

In the USA, diagnostics and therapeutics have traditionally gone through different regulatory streams with different evidentiary standards. Moreover, regulatory streams at the FDA were designed well before the advent of PM. Two separate and distinct regulatory streams, therefore, exist for therapeutics and medical devices, respectively. Through the FDA, the Center for Drug Evaluation and Research^[116](#fn116){ref-type="fn"}^ and the Center for Biologics Evaluation and Research^[117](#fn117){ref-type="fn"}^ evaluate drugs, biologics, and combination products, ^[118](#fn118){ref-type="fn"}^ whereas the Center for Devices and Radiological Health oversees medical devices.^[119](#fn119){ref-type="fn"}^ (see Figure [2](#fig2){ref-type="fig"}). This separation creates uncertainty about how best to satisfy regulatory requirements for co-development, what data should be submitted and how best to time the submission of relevant regulatory requirements.^[120](#fn120){ref-type="fn"}^ The existence of multiple paths for regulatory approval makes it confusing to determine which regulators approve CDx,^[121](#fn121){ref-type="fn"}^ especially if the test may have multiple intended uses.^[122](#fn122){ref-type="fn"}^ However, the appeal of having a paired therapeutic and diagnostic has led some companies engaged in the development of PM to attempt co-development, despite the myriad of difficulties they face.^[123](#fn123){ref-type="fn"}^

![National Human Genome Research Institute (NHGR) Regulation of Genetic Tests. Adapted from <http://www.genome.gov/10002335> accessed July, 23, 2015.](lsx030fig2){#fig2}

Recommendations to Overcome Barriers for Co-development {#sec3-4}
-------------------------------------------------------

Recommendations to overcome the barriers to co-development of therapeutics and diagnostics focus on implementing regulatory reforms that incentivize the co-development process, something the FDA attempted in its 2014 guidance.^[124](#fn124){ref-type="fn"}^ In general, stakeholders seek the alignment of regulations between therapeutics and diagnostics,^[125](#fn125){ref-type="fn"}^ greater regulatory clarity,^[126](#fn126){ref-type="fn"}^ and recognition of the complications of the co-development process.^[127](#fn127){ref-type="fn"}^ The creation of a single regulatory stream would ease the burden on companies seeking regulatory approvals in the PM space.^[128](#fn128){ref-type="fn"}^ While co-development is strongly encouraged by the FDA, greater guidance on how to proceed with non-parallel development would aid the sizable majority of companies for which co-development is not possible.^[129](#fn129){ref-type="fn"}^

Recommendations also focus on improving clarity on cross-labeling requirements.^[130](#fn130){ref-type="fn"}^ Commentators note the lack of clear and common standards indicating what evidence is required to label drugs for a particular subgroup or for a particular genetic mutation.^[131](#fn131){ref-type="fn"}^ Greater clarity in labeling requirements would enhance patient care and the uptake of CDx (for example, pharmacogenetic tests).^[132](#fn132){ref-type="fn"}^ Clarity is needed on when cross-labeling is required and when it is simply recommended for informational purposes.^[133](#fn133){ref-type="fn"}^ Greater flexibility in labeling or in making labeling changes could create a more responsive system in which additional tests or diagnostics could be added to labels as improvements and innovations in diagnostics appear.^[134](#fn134){ref-type="fn"}^ Successful pairing of therapeutics and diagnostics could be enhanced through PMR to provide evidentiary support for labeling claims and by greater specificity in labeling requirements.^[135](#fn135){ref-type="fn"}^ For example, labels could provide consumers and prescribers with further information and assessment on predictive claims,^[136](#fn136){ref-type="fn"}^ the requirement for testing prior to taking a prescription,^[137](#fn137){ref-type="fn"}^ and information on the actions required depending on the results of the CDx test.^[138](#fn138){ref-type="fn"}^

Challenge: Regulation of Genetic Testing {#sec3-5}
----------------------------------------

As a subset of in vitro diagnostic tests, genetic tests may determine therapeutic choices or other personalized interventions.^[139](#fn139){ref-type="fn"}^ Genetic tests fall into two categories: LDTs and genetic test kits. LDTs are the most common and are generally developed in a single laboratory to which patient samples must be sent for analysis.^[140](#fn140){ref-type="fn"}^ LDTs can be thought of as 'in-house' genetic tests. Genetic test kits, on the other hand, comprise a set of reagents and analytical information sold together to multiple testing laboratories.^[141](#fn141){ref-type="fn"}^ Some genetic tests are marketed directly to consumers; such DTC genetic tests have been the subject of considerable controversy.^[142](#fn142){ref-type="fn"}^ In the following sections, we expand on the subthemes relevant to PM in 39 articles on genetic testing, namely: lack of regulations on LDTs (17 articles); lack of guidance on LDTs in the approvals process (9 articles); inadequate regulation of DTC genetic tests (6 articles); an underappreciation for the potential harms DTC genetic tests pose (6 articles); the problem of misleading advertising associated with DTC genetic tests (5 articles); the unsuitability of current regulations for DTC genetic tests (4 articles) and LDTs (2 articles); perceived difficulties with regulating LDTs (3 articles); a lack of clarity on how to regulate DTC genetic tests (3 articles); and the lack of clinical utility measures that hinder the uptake of LDTs (2 articles).

Three measures determine the validity and utility of genetic tests. Analytic validity determines whether and how well the test measures or determines the presence of the biomarker.^[143](#fn143){ref-type="fn"}^ Clinical validity determines whether there is a correlation between the targeted clinical condition and the biomarker.^[144](#fn144){ref-type="fn"}^ The third and more difficult measurement to determine is clinical utility. It asks: Does the test lead to increased human health, or a beneficial medical outcome?^[145](#fn145){ref-type="fn"}^ Quality tests should therefore be analytically and clinically valid, as well as clinically useful.

These three measurements are applied differently and unequally to LDTs and to genetic test kits, due in part to the different regulatory regimes that govern the different types of tests.^[146](#fn146){ref-type="fn"}^ This creates significant regulatory challenges.^[147](#fn147){ref-type="fn"}^ In the USA, regulatory oversight of genetic testing is split between three federal government agencies: the FDA, the CMS, and the Federal Trade Commission (FTC), which is the federal consumer protection agency. Each of these agencies has a different mandate and applies different standards. This has led to numerous complaints of a lack of adequate, rigorous, and consistent regulation.^[148](#fn148){ref-type="fn"}^ Despite the novel issues that genetic tests raise, no new regulatory system has been created for their approval. The existing regulatory structure creates false separations based on where and how genetic tests are used, rather than focusing on their validity and utility regardless of how they are applied.

The FDA has the authority to regulate genetic test kits as medical devices based on safety and efficacy under the Food, Drug and Cosmetic Act.^[149](#fn149){ref-type="fn"}^ The regulations in that act create a stratified or tiered system of approval requirements based on the level of risk posed by the device to the patient or the user based on intended use and the indications for use. Class I devices are low risk and generally exempt from the requirement for a 510(k) premarket notification (a process establishing that the device is substantially equivalent to a device already marketed). As such, class I devices generally require only broad controls such as registration, labeling, and good manufacturing practices. Class II devices are classified as moderate risk and generally require a 510(k) premarket notification prior to marketing. Devices considered class III (highest risk classification) require a premarket approval (PMA) for clearance by the FDA to market the device. The PMA process is more complicated and requires the submission of clinical evidence to support the claims being made about the device.^[150](#fn150){ref-type="fn"}^

With respect to genetic tests, FDA regulations require evidence that genetic test kits are analytically and clinically valid, although evidence of their clinical utility is not required.^[151](#fn151){ref-type="fn"}^ This is a point of concern, given that ensuring genetic testing leads to positive health outcomes (clinical utility) is critical for both patient welfare and reimbursement decisions. Until recently, the FDA has exercised its regulatory authority sparingly and only as it applies to genetic test kits---choosing to leave LDTs regulated only by the less stringent Clinical Laboratories Improvement Amendments (CLIA) regulations.^[152](#fn152){ref-type="fn"}^ The imposition of different standards on genetic test kits and LDTs is the most pressing issue for those who want to have equal, reliable testing for all genetic tests. Ongoing criticism of the differences between FDA and CLIA regulation has led to significant policy action at the federal level.

The CMS oversees clinical laboratories and regulates LDTs under the authority of CLIA.^[153](#fn153){ref-type="fn"}^ The CMS ensures that LDTs are analytically valid but does not require evidence that LDTs meet the standards of either clinical validity or utility.^[154](#fn154){ref-type="fn"}^ CLIA regulations categorize laboratory tests as either 'waived' or 'non-waived' according to whether they are low, moderate, or high complexity tests. Tests that are either moderate or high complexity are subject to additional requirements to ensure their safety. Higher complexity tests are generally grouped into specialty areas that are subject to more rigorous external proficiency testing to verify their ongoing analytic validity. While molecular and genetic tests are considered high complexity, they have not been designated as a subspecialty and, therefore, are not subjected to the most stringent testing available under CLIA.^[155](#fn155){ref-type="fn"}^

In addition, significant concern exists about a lack of rigorous and consistent regulation of DTC genetic testing, which enables consumers or patients to access their genetic information directly from a testing company.^[156](#fn156){ref-type="fn"}^ For many years the FDA did not exercise its jurisdiction over DTC genetic tests, creating yet another group of genetic tests without rigorous regulatory oversight. This situation is changing as the technology advances and as the FDA asserts its authority over genetic testing. Whether the FDA regulatory approach is appropriate for DTC testing is an open question. Proponents claim that many of the risks associated with DTC genetic testing are speculative and that it has intangible benefits, including patient autonomy and privacy.^[157](#fn157){ref-type="fn"}^ DTC genetic tests continue to create controversy, however, because they are advertised directly to consumers and the advertising may be fraudulent and/or may misrepresent the benefits for the consumer.^[158](#fn158){ref-type="fn"}^ Misleading claims are under the regulatory purview of the FTC, which protects consumers from unfair and deceptive business practices and from false and misleading advertising claims.^[159](#fn159){ref-type="fn"}^ Concerns about the claims made by DTC genetic testing providers have prompted calls for the FTC to exercise its authority to protect consumers, some of whom may make medical decisions to either forgo treatment, based on a false-negative test results, or undertake drastic medical procedures, such as prophylactic surgery, based on false-positive test results.^[160](#fn160){ref-type="fn"}^ The FTC has largely ignored evaluating the truth of health marketing claims made by DTC genetic testing companies, which leaves the field open to fraudulent claims.^[161](#fn161){ref-type="fn"}^

Current perceptions persist that advertising of DTC genetic tests is false and/or misleading to such an extent as to undermine consumer and provider confidence in the veracity and utility of all genetic tests.^[162](#fn162){ref-type="fn"}^ The perception that the FTC is not taking action against DTC companies challenges the uptake of legitimate genetic tests.^[163](#fn163){ref-type="fn"}^ Exacerbating this situation, there is a plethora of reasons for an individual to purchase a DTC test outside of health, including recreational, educational, and ancestry. This can be exploited by DTC companies in marketing and promotional materials.

Recommendations for Regulation of Genetic Testing {#sec3-6}
-------------------------------------------------

Regulatory recommendations for improving genetic testing in PM include greater involvement of healthcare professionals, ^[164](#fn164){ref-type="fn"}^ greater regulation of both DTC^[165](#fn165){ref-type="fn"}^ tests and LDT^[166](#fn166){ref-type="fn"}^ at the federal level to ensure quality, and the creation of a comprehensive genetic test registry.^[167](#fn167){ref-type="fn"}^

### LDT Recommendations {#sec3-6-1}

The most common recommendations concerning LDT testing are to increase regulatory oversight^[168](#fn168){ref-type="fn"}^ and evidentiary standards.^[169](#fn169){ref-type="fn"}^ Recommendations include expanding FDA oversight to cover LDTs^[170](#fn170){ref-type="fn"}^ (likely to occur in 2016); expanding evidentiary standards to include evidence of clinical validity and utility;^[171](#fn171){ref-type="fn"}^ and ensuring that LDT laboratories undergo proficiency testing, certification, or increased accreditation requirements.

Some critics who have complained that CLIA regulations are inadequate to ensure the quality of genetic tests advocate for the creation of a genetic subspecialty. This would involve an external review and a more rigorous examination of tests resulting in higher quality review.^[172](#fn172){ref-type="fn"}^ Furthermore, commentators over the last 15 years have criticized the FDA's unwillingness to hold DTC genetic tests^[173](#fn173){ref-type="fn"}^ and LDTs^[174](#fn174){ref-type="fn"}^ to the same standards it uses for test kits. After numerous studies and reports calling for increased oversight action,^[175](#fn175){ref-type="fn"}^ the FDA issued draft guidance on October 3, 2014, thus asserting its statutory authority and signaling its intention to exercise regulatory oversight over LDT. The draft guidance outlines the phasing in of a plan that extends the stratified risk-based framework applied to medical devices for premarket notifications and approvals to all genetic tests, regardless of where they are developed. Tests for rare diseases that meet the definition of a Humanitarian Use Device would be subject to discretionary authority regarding the need for PMA.^[176](#fn176){ref-type="fn"}^ The new guidance requires notification to the FDA of LDTs as a no-fee alternative to registration and listing of LDTs. It further requires SAE reporting and a demonstration of clinical validity of LDTs.^[177](#fn177){ref-type="fn"}^

The guidance has not been met with universal approval. Some articles express concern that increasing FDA oversight of LDTs will increase cost and delay for manufacturers. Others are concerned with the chilling effect on swift and ongoing improvement and innovation due to oversight bureaucracy, and some assert that the FDA lacks statutory authority to expand its oversight to LDT.^[178](#fn178){ref-type="fn"}^ Statutory oversight aside, concerns about the FDA's workload and its ability to oversee the large number of LDTs will need to be weighed against the greater evidence of validity and utility derived from FDA oversight. Following a series of FDA workshops, several hearings before the House Energy and Commerce Committee Subcommittee on Health, and a lengthy public comment period, the FDA has indicated it will issue its final guidance in 2016.^[179](#fn179){ref-type="fn"}^

On November 18, 2016, the FDA announced that it would not issue a final guidance for the oversight of LDTs.^[180](#fn180){ref-type="fn"}^ This leaves the current uneven patchwork of oversight on DTC, LDT, and genetic test kits in place, and the concomitant problems discussed above. In January 2017, the FDA released a discussion paper laying out issues that could guide a legislative solution and signaling that the issue has not yet been put to rest.^[181](#fn181){ref-type="fn"}^ In particular, the FDA points to the need for 'well-curated databases' of scientific evidence on clinical validity and other measurements that could be used to establish the accuracy and validity of LDTs.^[182](#fn182){ref-type="fn"}^

While backing away from guidance on LDTs, in July 2016, the FDA issued draft guidances on next generation sequencing (NGS) genetic tests as part of the PMI^[183](#fn183){ref-type="fn"}^. While these guidances signal the FDA's intention to regulate IVD based on NGS as part of the PMI, the FDA has taken an approach aimed at facilitating the use of these tests and easing the scientific regulatory requirements.^[184](#fn184){ref-type="fn"}^ The first guidance called for more public databases of genetic variants and their use in establishing clinical validity of NGS tests.^[185](#fn185){ref-type="fn"}^ The second guidance discussed the need for standards in the designing, developing, and validating of NGS-based tests for germline diseases as part of the PMI.^[186](#fn186){ref-type="fn"}^

In addition to greater quality assurances of LDTs, a number of authors advocate for the creation of a mandatory genetic test data registry.^[187](#fn187){ref-type="fn"}^ Currently, there is a voluntary test registry hosted by the National Institutes of Health\'s (NIH) National Center for Biotechnology Information.^[188](#fn188){ref-type="fn"}^ Despite recommendations by the Secretary\'s Advisory Committee on Genetics, Health, and Society to make registration mandatory for all genetic tests, it does not include all genetic tests. Additionally, the test registry may be more useful to consumers if standardized fields, such as the molecular basis of the tests and the methods used for testing, are included in the registry and uniformly entered to be easily searchable.^[189](#fn189){ref-type="fn"}^

### DTC Recommendations {#sec3-6-2}

Although there are a number of US states that currently either prohibit DTC testing or mandate professional involvement in ordering or interpreting genetic test results, many states do not regulate provision of DTC tests.^[190](#fn190){ref-type="fn"}^ Recommendations include federal regulation of DTC tests through mandatory inclusion of professionals, including genetic counselors, in either the test ordering or the provision of test results.^[191](#fn191){ref-type="fn"}^ DTC companies should be responsible for providing greater quality assurances and more accurate information about their tests.^[192](#fn192){ref-type="fn"}^ Failing these changes, the numerous calls for increased comprehensive federal regulation by the FDA using its stratified risk-based approach^[193](#fn193){ref-type="fn"}^ and FTC^[194](#fn194){ref-type="fn"}^ oversight of DTC testing are likely to continue. In November 2013, the FDA signaled a new readiness to flex its authority over DTC tests in a way it had not done previously. It barred 23andMe, a DTC genetic testing company, from using its broad-based genetic screen without regulatory approval.^[195](#fn195){ref-type="fn"}^ In October 2015, 23andMe became the first DTC company to be granted FDA approval for its DTC test kits, a fact it heralded on its website.^[196](#fn196){ref-type="fn"}^ Continuing the trend to greater scrutiny of DTC tests by the FDA, in November 2015 the FDA sent letters to three DTC genetic testing companies, DNA4Life, DNA-CardioCheck, and Interleukin Genetics, for marketing unapproved genetic tests.^[197](#fn197){ref-type="fn"}^ However, on April 6, 2017, the FDA softened its initial decision, permitting 23andme to offer DTC genetic testing for 10 diseases or conditions, including Parkinson\'s disease, late-onset Alzheimer\'s disease, Celiac disease, and several hereditary conditions.^[198](#fn198){ref-type="fn"}^ While paving the way for future genetic predisposition tests from 23andme and similar DTC companies, the FDA clarified its expectations with regard to the accuracy, reliability, and clinical relevance of such tests through special controls.^[199](#fn199){ref-type="fn"}^ Further, the FDA has created a regulatory pathway for DTC genetic predisposition tests that will expedite approvals from premarket review after an initial de novo application.^[200](#fn200){ref-type="fn"}^ Despite relaxing its stance on some genetic tests, DTC diagnostic tests for conditions such as BRCA, for example, are not included in the authorization granted to 23andme.^[201](#fn201){ref-type="fn"}^

In addition to FDA regulation of DTC testing, expansion of other federal protections such as privacy protections under The Genetic Information Non-Discrimination Act (GINA),^[202](#fn202){ref-type="fn"}^ or the FDA Sentinel (postmarketing surveillance)^[203](#fn203){ref-type="fn"}^ program,^[204](#fn204){ref-type="fn"}^ could further bring DTC testing into the regulatory fold. Calls for additional oversight of DTC communications and advertising by the FTC are joined by calls to 'regulate' misleading or harmful claims on DTC tests by using a Tort law standard or reasonableness in negligence law,^[205](#fn205){ref-type="fn"}^ and by requiring DTC testing information and risk predictions to be harmonized with industry standards.^[206](#fn206){ref-type="fn"}^ The creation of uniform standards for risk predictions and other DTC communications could bring DTC genetic tests in line with other medical device regulation and hold riskier tests to a higher standard of examination.^[207](#fn207){ref-type="fn"}^

Finally, concerns about lax federal regulation and misleading advertising of DTC genetic testing has led several states to mandate that genetic test results be returned to a physician or learned intermediary with the skill to meaningfully interpret test results. The hope is that such meaningfully interpretation of genetic test results will lead to better healthcare decision making.^[208](#fn208){ref-type="fn"}^ While physicians have a duty, in many cases a legal duty, to impart incidental findings from genetic tests to a patient, the regulations are unclear regarding the duties of generators, providers, and interpreters of genetic test results.^[209](#fn209){ref-type="fn"}^ This confusion with respect to communication leads to quality control issues and inconsistent standards.

Challenge: Uncertain Regulations on Evidentiary Standards {#sec3-7}
---------------------------------------------------------

In the following sections, we expand on the subthemes relevant to PM in 55 articles that discuss issues with evidence standards, namely existing standards that are unreasonable (11 articles) or unclear (11 articles) in a PM context; the failure of evidence produced by companies to meet regulatory requirements (12 articles), including the inability of many companies to carry out phase IV trials (8 articles); the increased cost associated with meeting regulatory data standards (7 articles); the inadequacy of data to expand applications to broader indications (4 articles); the delay that meeting evidentiary standards can cause (4 articles); and the unclear standards for clinical utility (2 articles).

PM developers find the data and evidentiary requirements for regulatory approval unclear.^[210](#fn210){ref-type="fn"}^ Vague evidentiary standards and requirements act as a barrier to the translation of PM products as companies struggle to develop appropriate evidence for approval and reimbursement.^[211](#fn211){ref-type="fn"}^ Whereas the FDA requires evidence of safety and efficacy, it does not require measures of clinical utility---that is, evidence that overall health outcomes are improved in a clinical setting. Payers, making choices about which therapies to cover, require this additional layer of evidence as a basis of payment decisions. In other words, what matters to a payer is whether a therapy is ultimately proven to be clinically useful and that it is a cost-effective alternative to existing therapies. These considerations are currently outside the evidence required for regulatory approval.

Lack of uniformity and clarity in data requirements between statutes, regulators, and payers poses challenges for developers. Not only is there lingering uncertainty about what data are required, but also when that data should be incorporated into the FDA investigational new drug application (IND) process.^[212](#fn212){ref-type="fn"}^ This is especially evident when data about a potential effect in a subpopulation or a relevant biomarker for that population emerge during a clinical trial. Further, it is not clear how the FDA will use the data that are submitted, and whether the data will be sufficient to validate a biomarker, or to permit the subpopulation effects to be generalized to the wider population. Manufacturers are concerned that evidence of subpopulation effects may be used to limit the application of a drug or device, rather than expand its application.

In addition to these concerns, the FDA can require companies to conduct PMR, otherwise known as phase IV studies, to collect evidence on how the therapeutic or device is working in clinical practice, and what SAE might have been reported with its use.^[213](#fn213){ref-type="fn"}^ PMR are undertakings by companies to continue to collect evidence following regulatory approval; however, research shows that there is very low compliance with these commitments.^[214](#fn214){ref-type="fn"}^ Such low compliance masks previously unknown SAE, but also does not reveal new uses for a drug or how the drug functions in different patient subgroups.^[215](#fn215){ref-type="fn"}^ While regulators are reluctant to extrapolate from subpopulation data to other populations, groups, and ethnicities,^[216](#fn216){ref-type="fn"}^ the expense involved in providing evidence on additional populations (and potentially undertaking an additional clinical trial on the subgroup) may be prohibitive to developing PM products.^[217](#fn217){ref-type="fn"}^ In the case of pharmacogenetic tests, developers remain uncertain whether they will be required to undertake phase IV studies, and whether that evidence might lead to restrictions on approvals in genetic subpopulations.^[218](#fn218){ref-type="fn"}^

There are a number of reasons that companies do not fulfill their PMC and do not provide ongoing data to the regulators. First, PMR are expensive and time consuming.^[219](#fn219){ref-type="fn"}^ Second, they are notoriously difficult to conduct, requiring data gathering of physician and patient reporting of SAE, which are widely underreported.^[220](#fn220){ref-type="fn"}^ Such detailed assessments of clinical efficacy are very difficult to provide.

Recommendations to Improve Evidentiary Requirements {#sec3-8}
---------------------------------------------------

Recommendations for bringing better quality evidence to regulators generally fall on the manufacturers. There is a call for submissions to regulators to provide higher quality evidence that is not only useful to payers and providers, but also that anticipates the need to show cost-effectiveness for reimbursement.^[221](#fn221){ref-type="fn"}^ Additional recommendations for regulators include the use of less restrictive, more flexible, and innovative approaches to PM clinical trials and approvals.^[222](#fn222){ref-type="fn"}^ This might be achieved by allowing alternative forms of evidence,^[223](#fn223){ref-type="fn"}^ initially using exploratory or modeling analysis combined with corroborative evidence,^[224](#fn224){ref-type="fn"}^ or permitting the use of comparison or equivalency data which relies on prior, similar submissions^[225](#fn225){ref-type="fn"}^ (as in follow on biologics). In particular, clear technical guidance on generation and submission of genomic data, clinical evidence standards, and the use of biomarkers in both drug development and pharmacogenetic studies is needed as an incentive to stimulate manufacturers to design their studies to capture these data.^[226](#fn226){ref-type="fn"}^ Pathways to make the generation of these data less expensive and time consuming might include leveraging public--private partnerships and large cross-institutional studies involving non-industry actors as a means of validating biomarkers. Developing industry guidelines to create more accurate methods for predicting drug safety and pooling resources^[227](#fn227){ref-type="fn"}^ to address the costs associated with bringing PM products to market would help reduce the time and costs of evidence generation.

Non-compliance with PMR commitments has become such a problem that Congress mandated the FDA to work through the backlog of PMR commitments and provide annual reports on progress.^[228](#fn228){ref-type="fn"}^ To date, the backlog has been reduced, and the FDA is working to ensure greater compliance.^[229](#fn229){ref-type="fn"}^ In furtherance to fulfilling these obligations, the FDA has continued its commitment to the Sentinel program which tracks performance of medical products by accessing a number of data sources, including electronic health records (EHR), patient registries, and insurance datasets to better identify SAE and anticipates much better PMR of medical products.^[230](#fn230){ref-type="fn"}^

Challenge: Information Systems and Privacy {#sec3-9}
------------------------------------------

The literature on regulation of information systems reveals three main subthemes highlighting a tension between the interests of patients and developers of PM therapies and devices. In this section, we expand on privacy concerns (26 articles); sample storage and collection concerns (14 articles); and the heterogeneous nature of sample storage and collection regulations (9 articles). Issues of patient and research subject consent are mentioned in all three subthemes.

Human tissue samples, housed in hospital pathology laboratories and biobanks, support PM R&D. The samples are often used to determine genetic contributions to diseases when linked with phenotypic information and to test for biomarkers. The value of tissue samples is greatly enhanced when linked to medical health records or other data on disease histories and phenotypes. An ability to aggregate data across multiple national and international research facilities is crucial for scientific research, especially for rare disease phenotypes where information may be scarce. Consequently, pathological samples and EHR containing personal health information are simultaneously private patient information and valuable resources for drug companies and PM developers. Information systems that manage PM research data and samples are in tension, trying to balance the access and use requirements of researchers and developers with the autonomy and privacy interests of research participants.

### Informed Consent and Privacy {#sec3-9-1}

Information and data management systems and the associated legal and ethical issues raised with respect to consent and privacy of personal or protected health information (PHI) are central to PM R&D. This is because much PM development involves use of biospecimens and knowledge of patient genetics or biomarkers. Since genetic information may reveal both personal and familial health or ancestry information, issues of consent and privacy are paramount in genetic studies and tests used in PM R&D. The legal requirement for researchers to obtain informed consent from research subjects is imbedded in US federal regulations that deal with human subjects research supported by the federal government.^[231](#fn231){ref-type="fn"}^ The Common Rule governs human subjects research on products regulated by the FDA. These regulations also cover research on human tissues and associated information that can be linked to an identifiable individual.^[232](#fn232){ref-type="fn"}^ In addition to the Common Rule, federal regulations governing the use of PHI were implemented in 2003 under the Health Insurance Portability and Accountability Act (HIPAA) of 1996.^[233](#fn233){ref-type="fn"}^ HIPAA applies to three categories of healthcare institutions, known as HIPAA covered entities: most healthcare providers, most health plans (insurers), and healthcare clearinghouses. HIPAA imposes limitations on the research uses and disclosures of identifiable patient information, requiring patient authorization for specific uses of certain PHI. HIPAA privacy rules do not apply to health information held by data brokers, websites, credit bureaus, disease registries, health researchers, disease advocacy organizations, law enforcement agencies, or others as defined under the act.^[234](#fn234){ref-type="fn"}^

The scope of informed consent as it relates to PM, in particular, is complex and important. Generally, consent to conduct research on a person or that person\'s tissues relates to a specific research activity that can be well described and for which consent can be meaningfully given or withheld based on knowledge of risks and alternatives. A problem for the PM research enterprise relates to whether a patient can give a non-specific consent to future research, without knowing what the nature and attendant risks of that research might be. Many argue that consent to research that is not yet defined cannot be informed and does not respect patient autonomy as required.^[235](#fn235){ref-type="fn"}^ While the acceptability of consent to future research is hotly debated, the ability to obtain consent to future undefined research is central to PM development. Much PM research comes from a retrospective analysis of clinical trials to determine what subpopulations might derive a therapeutic effect. Consequently, the need to reexamine tissue samples for a different research outcome than originally described often arises. Re-consent of tissue donors for a different research objective may be neither feasible nor possible, and it is unclear whether it is required in all circumstances.

PM developers complain that the balance of regulations often emphasize individual autonomy and control over personal health information rather than the research enterprise and creation of a research platform of genetic information and resources, creating a barrier to PM development.^[236](#fn236){ref-type="fn"}^ Indeed, the regulations reflect a tension between balancing privacy and patient autonomy against a need for transparency, greater information gathering and sharing of research resources to advance PM.^[237](#fn237){ref-type="fn"}^

Complex layers of oversight from local institutional review boards (IRBs) to federal regulations protect individual autonomy and privacy, necessitating re-consent of research subjects, allowing subjects to withdraw from studies, and preferring anonymity and coded samples that make it more difficult to link PHI to tissue samples.^[238](#fn238){ref-type="fn"}^ Finding the right balance between researcher needs and subject protections is an ongoing regulatory exercise. In 2015, the Department of Health and Human Services proposed changes to the Common Rule^[239](#fn239){ref-type="fn"}^ that would require informed consent for research on biospecimens even if not linked to identifiable information. In addition, the changes would permit a broad consent to unspecified future research, heretofore not permitted. While the stated purpose for the changes includes increased simplicity and transparency for researchers, and additional protections for individual research subjects, the proposed rules are very controversial and some implicate individual privacy concerns. Some argue that they unduly favor researchers over patients, and 'demand that patients accept a one-time grab at all data, for any purpose, in order to provide broad access to others with no promised informational or other return and no mechanism to reciprocate patients' altruism'.^[240](#fn240){ref-type="fn"}^ On January 19, 2017, the final Common Rule was published^[241](#fn241){ref-type="fn"}^. Changes that required consent for non-identifiable biospecimens were eliminated, but changes that provided the ability to use a broad consent for future research were retained^[242](#fn242){ref-type="fn"}^.

A further regulatory barrier to PM is the heterogeneous and inconsistent regulations relating to human subjects research and biobanking, particularly the collection, sharing, and storage of data.^[243](#fn243){ref-type="fn"}^ There is a lack of harmonization both nationally and internationally between regulations covering the storage and use of biospecimens or use of PHI. PM developers and advocates argue that inconsistent regulations and conflicting standards create a climate of uncertainty that impedes the flow of both research materials and information between researchers and laboratories.^[244](#fn244){ref-type="fn"}^ Further barriers are created by inadequate and conflicting regulations to protect and use PHI, leading to improper use of that information and potential discrimination.^[245](#fn245){ref-type="fn"}^ Conflicting regulations exist not just between countries but within national systems.^[246](#fn246){ref-type="fn"}^ In the USA, federal regulations have differing definitions of and rules about what constitutes human subjects research, and whether and how informed consent for the use of tissue samples may be obtained. Adding to the complexity, both the federal Common Rule and HIPAA specifically leave room for individual states to create stricter standards on disclosure and use of biospecimens and PHI. State laws affecting the use of tissue and associated data in scientific research are found in a variety of sources, including medical records laws, privacy and health privacy laws, genetic testing/genetic information laws, and human subject protection laws. These laws are often different and inconsistent both among and within states. Regulations may impose different limits on uses of biospecimens and associated data and may offer different scopes of protection.^[247](#fn247){ref-type="fn"}^

The lack of regulatory clarity on how biospecimens and PHI can be shared and with whom has led to real concerns about individual privacy. This is particularly acute in genetic research since sensitive personal health information can now be revealed through genetic analysis of tissue samples using increasingly powerful sequencing tools that often reveal incidental health information. In the USA, despite the protections of the GINA, which forbids health insurers and employers from misuse of genetic information, patients continue to be fearful of discrimination after genetic testing. Where health insurers control access to care and testing in the USA, concerns about improper use of genetic information have a chilling effect on research into genetics of diseases so critical to PM.^[248](#fn248){ref-type="fn"}^

Of continued concern is the lack of HIPAA protection for the medical and personal health information collected by the PMI. It is, as yet, unclear exactly how the biospecimens and associated data will be collected and stored, whether in a federal registry or in different states (each with different and sometimes conflicting regulations). Federal agencies including the NIH are not 'covered entities' under HIPAA and therefore the privacy rules do not apply, even if the PHI originated from a HIPAA covered entity. Once an HIPAA-covered entity shares PHI with a non-covered entity, the information generally passes outside the scope of the HIPAA privacy rule and beyond the jurisdiction of HIPAA oversight. The question of how the PHI of millions of volunteers will be adequately protected under the PMI is a pressing question.^[249](#fn249){ref-type="fn"}^

Recommendations on Management of Information {#sec3-10}
--------------------------------------------

Recommendations to remove information management barriers include creating, improving, and harmonizing practices, guidelines, and policies for information sharing (4 articles). Most recommendations focus on improving biospecimen collection and storage (14 articles), and on creating stronger consent and privacy protections (7 articles). While some recommendations focus on systemic solutions, such as encrypting PHI between researchers and physicians (1 article), others focus on getting consent from patients to archive genetic data for future use (1 article), and moving toward the use of research advance directives (1 article). These recommendations support broader consents aimed at facilitating future research uses of biospecimens and PHI.

Collection procedures could be improved by ensuring samples are collected and sequenced in advance of clinical trial submissions. This should help with prospective biomarker identification, and ensure that enough genetic variants are represented and that samples from the intended patient population are available for submission in clinical trials. Strong protocols that include sample collection and storage procedures would also enable retrospective associations with safety and efficacy outcomes and retrospective identification of biomarkers.

In response to the PMI, the FDA created precisionFDA, an 'online, cloud-based portal that will allow scientists from industry, academia, government and other partners to come together to foster innovation and develop the science behind a method of "reading" DNA known as next-generation sequencing'.^[250](#fn250){ref-type="fn"}^ Using NGS, precisionFDA aims to create a web platform to aid researchers in sharing and learning about individual genetic variations, with the hope that these actions will lead to PM knowledge and innovations. PrecisionFDA hopes to leverage tools for greater information sharing and to help with the validation of genetic sequences and ultimately biomarker identification. Tools include the creation of reference genomes that will be posted online.

To address privacy concerns, authors recommend more transparent privacy laws with legal supports that protect individual interests in health information.^[251](#fn251){ref-type="fn"}^ These might take the form of stronger federal regulations that cover more than just federally funded research (as in the Common Rule) and policies to handle genetic discrimination.^[252](#fn252){ref-type="fn"}^ Recommendations to address the misuse of genetic information in contexts currently not covered by GINA, such as life, disability, and long-term care insurance or coverage of existing conditions with a genetic component, could strengthen PHI protections.^[253](#fn253){ref-type="fn"}^ Extending coverage to include full medical histories in the statutory definition of 'genetic information' and to misuse of that information to other contexts, like schools and biobanking, would provide patients with greater protections.^[254](#fn254){ref-type="fn"}^

In the context of the PMI, in November 2015 the White House published Privacy and Trust Principles, which recommended, inter alia, that '\[m\]ultiple tiers of data access---from open to controlled---based on data type, data use and user qualifications should be employed to ensure that a broad range of interested communities can utilize data while ensuring that privacy is safeguarded and public trust is maintained'.^[255](#fn255){ref-type="fn"}^ On May 25, 2016, the White House published its PMI Data Security Policy Principles and Framework.^[256](#fn256){ref-type="fn"}^ The recommendations require each organization involved in the PMI to create its own data security system, but call for 'processes and controls to address both internal and external threats, and assure the confidentiality, integrity, and availability of data generated and contributed during precision medicine activities'.^[257](#fn257){ref-type="fn"}^ While requiring organizations embrace standard best practices, the Data Security Policy Principles and Framework does not create a harmonized system across the diverse set of organizations involved in the PMI. Instead, organizations must ensure that their security framework adequately addresses 'the security risks they face and is consistent with the PMI Data Security Policy Principles and Framework'. The heterogeneous and myriad of organizations involved in the PMI are a particular challenge for data security in the PMI. With regard to a framework for data security, the report outlines a framework developed by the National Institute for Standards and Technology for Improving Critical Infrastructure Cybersecurity, Version 1.0, that enables five simultaneous and continuous functions---Identify, Protect, Detect, Respond and Recover---to assess cybersecurity and data security performance.^[258](#fn258){ref-type="fn"}^

In addition, articles recommend increasing federal funding of biobanks as a means to achieving higher standards and more harmonization of rules and practices relating to data management and security. With regard to the PMI, on May 26, 2016 the NIH awarded \$142 million over five years to the Mayo Clinic in Minnesota to establish the world\'s largest research-cohort biobank. The PMI cohort biobank will collect, store, and distribute biospecimens for research.^[259](#fn259){ref-type="fn"}^ Finally, numerous articles recommend greater adoption and use of EHR and of systems to facilitate protected transfer and storage of those EHR.^[260](#fn260){ref-type="fn"}^ Use of EHR is a cornerstone of the PMI as well.

Challenge: Incentives to Enter PM space and IP barriers {#sec3-11}
-------------------------------------------------------

According to the literature, intellectual property rights, particularly patents, create barriers to PM innovation, investment, and development in two distinct ways. First, PM developers argue that the patent system does not provide certain, predictable, strong rights that protect the substantial investment in PM drug and device development.^[261](#fn261){ref-type="fn"}^ PM developers call for stronger incentives where the market may not provide adequate financial reward. In contrast, patients, healthcare providers, and those unable to innovate due to blocking patents argue for a more open system, because existing patents on drugs and diagnostics stifle innovation, investment, and development of PM drugs and devices. These stakeholders argue that strong patent rights block further innovation,^[262](#fn262){ref-type="fn"}^ create patent thickets,^[263](#fn263){ref-type="fn"}^ and function as barriers to provider and patient access to drugs and devices.^[264](#fn264){ref-type="fn"}^ Limited empirical evidence supports either side of the patent debate.^[265](#fn265){ref-type="fn"}^ Here, we expand on the subthemes related to intellectual property (32 articles) and a lack of incentives for developers (20 articles).

Numerous articles assert that the high cost of drug development generally coupled with smaller financial returns for niche or personalized therapies necessitates strong and certain incentives to develop PM products. PM developers, in particular, decry a lack of certainty in scope and strength of patent protection.^[266](#fn266){ref-type="fn"}^ Industry stakeholders assert that consistent moves to amend and reform patent law have led to unpredictability in patent application and protections, ^[267](#fn267){ref-type="fn"}^ which in turn undermine investment and innovation in PM.^[268](#fn268){ref-type="fn"}^

However, not all commentators favor stronger patent rights for PM therapeutics. Several authors argue that patents hinder innovation in the PM space and can create barriers to patient access of drugs and genetic testing. Patent holders may block development of better tests, can prevent second opinion testing (especially through licensing practices, granting overly broad or exclusive license to underlying technology), may cover gene sequences such that development of genetic tests is hindered, and may create lack of innovation space through overly broad patent claims. In other words, broadly drafted or multiple overlapping patents can create an anticommon that stifles innovation because follow-on developers fear liability for patent infringement.^[269](#fn269){ref-type="fn"}^ What is clear from the literature is a lack of consensus on whether (i) patents act as necessary incentives to PM investment, innovation, and development such that they should be strengthened, or (ii) patents stifle innovation and investment, particularly in the device space, such that novel incentives are needed and patent rights should be curtailed. This tension runs through the literature and through the recommendations.

Some see the use of patents on subpopulations as a means of 'evergreening' or extending patent protection over a drug that has been repackaged as a PM for a smaller patient population. Even novel regulatory initiatives to entice innovation in the event of market failures may have an 'evergreening' effect such that they encourage unnecessary patient stratification (known as 'salami-slicing') in drug development without scientific justification^[270](#fn270){ref-type="fn"}^ and, thereby, stifle innovation in the PM space.

Unlike in pharmaceuticals, stronger and clearer patent law is not seen as the most significant incentive needed to support innovation and investment in PM tests and devices.^[271](#fn271){ref-type="fn"}^ One of the greatest barriers to PM device development with respect to intellectual property is general uncertainty about the applicability, strength, scope, and enforceability of patents on medical devices due to shifting patent law. The validity of many diagnostic patents has recently been called into question; therefore, it is unclear whether novel genetic tests will encounter patent thickets or infringe existing gene patents.^[272](#fn272){ref-type="fn"}^ Recent judicial rulings by the Supreme Court of the United States have created uncertainty as to the status of patents on both diagnostic and medical methods.^[273](#fn273){ref-type="fn"}^ Patents on gene-based molecular diagnostics may be problematic and fall afoul of recent rulings invalidating patent claims on naturally occurring molecules, including DNA sequences, and biomarker associations with drug dosing.^[274](#fn274){ref-type="fn"}^ Given the uncertainty in patent incentives, other forms of incentives may be needed to support the business model for device and diagnostic makers, which is leaner than that of pharmaceutical companies.^[275](#fn275){ref-type="fn"}^ Nevertheless, the current curtailing of the scope of PM-relevant patents serves as a natural experiment on the role of patent incentives in the diagnostics industry.

Recommendations on Incentive Systems and Patent Regulation {#sec3-12}
----------------------------------------------------------

Where the market fails to provide adequate financial incentives for investment and development of PM drugs and devices, authors recommend stimulating entry into the PM device market via additional incentives. Articles recommend economic and regulatory incentives, ranging from using existing statutes and regulations in innovative ways^[276](#fn276){ref-type="fn"}^ to creating entirely new incentive structures.^[277](#fn277){ref-type="fn"}^

Incentivizing PM development using existing patent systems is a recommendation many favor.^[278](#fn278){ref-type="fn"}^ Increased market exclusivity or extended patent periods for drugs marketed with a CDx could incentivize PM co-development.^[279](#fn279){ref-type="fn"}^ Other authors advocate for additional market exclusivity for diagnostics and novel manufacturing innovations.

However, recommendations for using patent incentives reflect the tension between proprietary rights and freedom to operate and access. Recommendations therefore range from calls for stronger, clearer patent laws^[280](#fn280){ref-type="fn"}^ to calls for limits on patent protection.^[281](#fn281){ref-type="fn"}^ Recommended mechanisms to enhance freedom to operate include the creation of gene-patent clearinghouses^[282](#fn282){ref-type="fn"}^ and patent pools.^[283](#fn283){ref-type="fn"}^ For genetic testing in particular, advocates for accessibility recommend using compulsory licensing,^[284](#fn284){ref-type="fn"}^ requiring reasonable royalties,^[285](#fn285){ref-type="fn"}^ or instituting march-in rights to overcome patent barriers on genetic test development.^[286](#fn286){ref-type="fn"}^ Several authors recommend the creation of a research exemption in the Patent Act^[287](#fn287){ref-type="fn"}^ that would insulate physicians and researchers from patent infringement liability, which could stimulate R&D in academic centers.^[288](#fn288){ref-type="fn"}^ Other exemptions such as protections from patent infringement suits for all diagnostic use^[289](#fn289){ref-type="fn"}^ or genetic testing for patient care purposes^[290](#fn290){ref-type="fn"}^ would likewise ease fears of infringement liability. Recent developments in case law, specifically *Alice Corp v. CLS Bank* on the application of patent protections on abstract ideas,^[291](#fn291){ref-type="fn"}^ continue to contribute to a lack of clarity about the applicability of patent protection for diagnostic tests. This continued uncertainty undermines patent protections as incentives on genetic diagnostics.

Several authors point to incentives for the development of pharmaceuticals for rare diseases under the US Orphan Drug Act^[292](#fn292){ref-type="fn"}^ (ODA)^[293](#fn293){ref-type="fn"}^ as a model. Incentives under the ODA have led to the development of drugs for smaller or less-lucrative markets; more than 400 drugs for rare diseases have been developed since 1983.^[294](#fn294){ref-type="fn"}^ Recommendations include repurposing the ODA for PM to incentivize market entry and provide market exclusivity while avoiding the uncertainties of the patent system.^[295](#fn295){ref-type="fn"}^ Others caution regulators to revisit provisions of the ODA to ensure that incentives are not misappropriated as science advances and disease categories shift.^[296](#fn296){ref-type="fn"}^ Additional recommendations include creating either an ODA-like regulatory pathway for PM-based drugs^[297](#fn297){ref-type="fn"}^ or a sui generis framework for PM products.^[298](#fn298){ref-type="fn"}^

Initiatives like the Humanitarian Device Exemption^[299](#fn299){ref-type="fn"}^ also provide a mechanism for device manufacturers to short-cut some evidentiary requirements normally associated with PMA from the FDA. However, some authors note that no period of market exclusivity is provided under the Exemption and suggest that market exclusivity is a necessary incentive for PM device development. Others recommend implementing incentive programs like the Priority Review Voucher Program,^[300](#fn300){ref-type="fn"}^ which provides incentives for R&D in drugs and biologics for rare pediatric diseases. The Voucher Program does not currently apply to medical devices.^[301](#fn301){ref-type="fn"}^

However, the 21st Century Cures Act provides medical device manufacturers in the PM space with additional incentives in the form of a quicker pathway through FDA approvals. Building on the priority review device pathway, the FDA will have a fast track for breakthrough medical technologies aimed at patients with life-threatening or irreversibly debilitating diseases or conditions, and limited alternatives.^[302](#fn302){ref-type="fn"}^ In addition, the Humanitarian Device Exemption has been expanded to include devices that treat conditions that affect up to 8000 people, up from the previous level of 4000 people.^[303](#fn303){ref-type="fn"}^

There was also support for more predictable funding for PM, for example, from a centralized fund or government funding of studies for smaller or underserved populations.^[304](#fn304){ref-type="fn"}^ President Obama\'s PMI is intended to create this kind of incentive. Other authors call on the FDA to create incentives for PM developers, including reduced FDA user fees for pharmaceutical companies that work with device manufacturers to incentivize co-development.^[305](#fn305){ref-type="fn"}^ Tax breaks and other incentives for investment in diagnostic companies to 'rescue' drugs that fail in phase II trials might stimulate creation of PGx data for smaller groups of patients^[306](#fn306){ref-type="fn"}^ and boost overall investment in PM. Finally, one author suggests forgoing incentive schemes in favor of increasing drug prices to reflect the costs involved in drug development and allowing the market to create incentives.^[307](#fn307){ref-type="fn"}^ Noting the current political climate in the USA regarding high drug prices^[308](#fn308){ref-type="fn"}^ and the need to keep drugs affordable in the CMS and in other national healthcare systems,^[309](#fn309){ref-type="fn"}^ this seems an unworkable policy recommendation.

Challenge: Reimbursement {#sec3-13}
------------------------

Uncertain or inadequate reimbursement by public and private payers of diagnostics and therapeutics creates one of the greatest barriers to the development and adoption of PM.^[310](#fn310){ref-type="fn"}^ PM developers and their investors already face a high chance of failure either in proof of concept or regulatory approval.^[311](#fn311){ref-type="fn"}^ However, following regulatory approval, additional uncertainty exists as to whether a PM product will be reimbursed. Lack of a positive reimbursement decision disincentivizes investment and creates barriers to use by prescribing and authorizing clinicians and patients.^[312](#fn312){ref-type="fn"}^ Clinicians may account for the financial state of a patient in recommending an expensive therapy, and, if no billing mechanism for a service (eg to order a specific PM diagnostic test) exists, clinicians have no financial incentive to perform that service.^[313](#fn313){ref-type="fn"}^ In public health systems, like those in Canada and the UK, the government is the payer and simply does not purchase or provide access to all existing therapies.^[314](#fn314){ref-type="fn"}^ The same is true in the USA, where health insurance plans are determinative of which treatments will be reimbursed. At a federal level, the CMS makes similar decisions with regard to Medicare and Medicaid. Here, we expand on the subthemes related to reimbursement from 87 articles, including diagnostics and drugs are reimbursed separately (22 articles); insufficient reimbursement (17 articles); the ineffectiveness of current health technology assessment (HTA) for evaluating PM (14 articles); clinical utility is not required for reimbursement decisions (13 articles); the mismatch between evidence required by payers and regulators (13 articles); a general lack of data (10 articles), more specifically, a lack of evidence on clinical utility (6 articles); a sense of uncertainty about the reimbursement of PM (6 articles); fixed reimbursement for technologies treating some diseases (5 articles); an unwillingness on developers' parts to invest without assured reimbursement (3 articles); a mismatch between evidence produced by companies and the payers' expectations (2 articles); and uncertainty over reimbursement for predictive genotyping (2 articles).

Ideally, health system payers, in making coverage decisions, require evidence that a therapy or test is clinically useful---that evidence demonstrates measurable increases in health or well-being in clinical application.^[315](#fn315){ref-type="fn"}^ This evidentiary issue is at the crux of the reimbursement barrier. Evidence of clinical utility is not required for regulatory approvals and yet it is necessary to meet the threshold for reimbursement.^[316](#fn316){ref-type="fn"}^ As mentioned above, CLIA regulations require that genetic tests meet a threshold of analytic validity^[317](#fn317){ref-type="fn"}^ and FDA regulations require evidence of safety and effectiveness in comparison with existing standard therapies, which includes data of analytical and clinical validity.^[318](#fn318){ref-type="fn"}^ Neither set of approval regulations requires evidence of clinical utility.

The same problems of inadequate data and insufficient evidence for successful navigation of the regulatory approvals system create difficulties for the reimbursement process. Evidence of clinical utility is often forthcoming only after PMR and longitudinal studies and is generally lacking in the field of PM.^[319](#fn319){ref-type="fn"}^ Data on clinical utility of genetic tests are particularly hard to develop, in part due to the difficulties correlating genetic tests and therapies with positive medical outcomes resulting from the underlying limitations of genetic predictors.^[320](#fn320){ref-type="fn"}^ Since all genetic variants are not directly associated with a disease or clinical condition, it is difficult to make clear medical predictions based on genetic information.^[321](#fn321){ref-type="fn"}^ Absent a clearer relationship between biomarkers, CDx, and improved health outcomes, payers remain skeptical and reimbursement remains uncertain.^[322](#fn322){ref-type="fn"}^

Questions remain about the level of evidence that is required to demonstrate clinical utility. Data required for regulatory approval differ not only in kind (analytical and clinical validity compared to clinical utility), but also in application of standards required for reimbursement decisions.^[323](#fn323){ref-type="fn"}^ There is no standardized method of preparing evidence of clinical utility, and uncertainty about what technical standards will be used creates confusion for test and drug manufacturers. This adds to the general uncertainty about the financial viability of PM therapies^[324](#fn324){ref-type="fn"}^ that already results from the expense of R&D and clinical trials, uncertain success of pharmaceuticals, and the smaller markets to which PM may be targeted.

Once a medical intervention is proven to be clinically useful, determining its reimbursement value is another barrier, one that is particularly troublesome with respect to CDx.^[325](#fn325){ref-type="fn"}^ First, the value of genetic information to overall health outcomes is indeterminate, let alone the value of tests that uncover that information.^[326](#fn326){ref-type="fn"}^ There is no agreed-upon set of parameters used to evaluate the reimbursement rate of CDx and little transparency in the reimbursement process.^[327](#fn327){ref-type="fn"}^ As a nascent field, it is unclear how to economically evaluate the worth of predictive testing for drug response.^[328](#fn328){ref-type="fn"}^

HTA and economic evaluation are traditionally used to evaluate the value of new pharmaceuticals and medical technologies relative to existing standards of care. HTA bodies have little experience with CDx and uses cost-effectiveness (a measure of the improvement in health outcomes relative to cost) and clinical utility measures, which may not be directly applicable.^[329](#fn329){ref-type="fn"}^ The interrelationship between PM therapy and CDx means the tests often follow the therapies, resulting in different timelines, different evidence, and interdependence, all of which complicate HTA and reimbursement decisions.^[330](#fn330){ref-type="fn"}^ Complicating the valuation exercises are multiple potential CDx, whose value may be linked to, or differ from, the value of the therapy.^[331](#fn331){ref-type="fn"}^ Traditionally reimbursement rates for diagnostics are much lower than pharmaceuticals, and are based on cost, as low as \$50 to \$100 per test, rather than value.^[332](#fn332){ref-type="fn"}^ Reimbursement policies based on cost do not recognize the clinical value or development costs of CDx^[333](#fn333){ref-type="fn"}^ thus, the CDx reimbursement rate is magnitudes lower than for its therapy. This is a major barrier to independent investment in the development of new and innovative CDx.^[334](#fn334){ref-type="fn"}^ In addition, the development of value-based analysis for reimbursement for PM is being developed on an ad hoc, case by case basis, leading to inconsistencies.^[335](#fn335){ref-type="fn"}^

### Comparative Effectiveness Research in Healthcare {#sec3-13-1}

Comparative effectiveness research (CER) compares the relative effectiveness of different therapies at improving health outcomes. It is particularly useful in identifying ineffective therapies. By contrast, cost-effectiveness measures the improvement in health outcomes relative to cost.^[336](#fn336){ref-type="fn"}^ CER has become an important part of the US healthcare industry. This follows the authorization of \$1.1 billion in The American Recovery and Reinvestment Act of 2009^[337](#fn337){ref-type="fn"}^ to conduct research comparing 'clinical outcomes, effectiveness, and appropriateness of items, services, and procedures that are used to prevent, diagnose, or treat diseases, disorders, and other health conditions'.^[338](#fn338){ref-type="fn"}^ Competing needs for scarce healthcare dollars has increased government and healthcare purchaser initiatives to determine the most effective use of those resources. CER compares the effectiveness as well as benefits and harms of existing healthcare interventions, including tests, surgeries, and drugs. As such, its objective is to find the most effective interventions between medical alternatives. Purchasers, governments, and consumers can then determine which treatments are most effective and least expensive between competing options. Cost-effectiveness measures remain controversial in the USA, because they are the basis for decisions about rationing of healthcare expenses.^[339](#fn339){ref-type="fn"}^

Since CER uses aggregate outcomes data to determine whether one treatment option is less effective than another, it can be very difficult for advocates of PM interventions with smaller groups of patients to contribute data for CER comparisons.^[340](#fn340){ref-type="fn"}^ Outcomes data for a particular condition may overwhelm a smaller subgroup of patients, unless the subgroup becomes the basis for comparative analysis.^[341](#fn341){ref-type="fn"}^ While CER can use different subgroups for analysis, doing so would require validating the subgroup as appropriate and looking at different data research tools.^[342](#fn342){ref-type="fn"}^ Exacerbating this research difficulty is the extremely high price of some PM drugs and tests, which, coupled with a small patient population, disadvantages them in CER. Those making reimbursement decisions are faced with questions about whether a test, drug, or treatment is worth purchasing. To justify higher prices, developers of PM will be required to provide more evidence than is required to support regulatory approval, which excludes considerations of cost.^[343](#fn343){ref-type="fn"}^

### Companion Diagnostic Reimbursement {#sec3-13-2}

Historical structures for reimbursement of diagnostics pose a barrier to investment in and adoption of CDx. In part, this barrier is the result of the different reimbursement structures, payers, and codes that exist for drugs and diagnostics.^[344](#fn344){ref-type="fn"}^ Twenty-two articles raise the disparate treatment of drugs and diagnostics at the payer level; however, these articles do not discuss the role of hospitals in decision making about diagnostics. Traditionally, diagnostic tests have been developed in hospital laboratories and the addition of tests has been under the purview of the director of the laboratory. As such, tests were part of the hospital budget with no explicit or formal process for their development or reimbursement. Thus, a non-transparent adoption process for diagnostics evolved. As more diagnostics are developed outside the hospital laboratory and sold as kits to hospitals, they become part of the formal budgeting process and must compete for those dollars. The prices for commercialized genetic tests and CDx are very expensive, compared to in-house developed diagnostics, even though diagnostic tests cost less than drugs. This makes it very difficult for a hospital diagnostic budget to absorb a CDx and puts pressures on laboratory directors to expand their budgets to accommodate new CDx.

Where insurance plans are concerned, pharmaceuticals often have a separate plan from medical services and are generally reimbursed at a higher rate than diagnostics.^[345](#fn345){ref-type="fn"}^ Drugs are reimbursed according to their value, whereas diagnostics are reimbursed according to their cost, depending on the materials and type of test.^[346](#fn346){ref-type="fn"}^ Pricing of drugs presents a balance between volume and price; in other words, the lower the volume, the higher the price that may be charged to make a profit. However, if the patient population is small, different incentives must be found or the cost to patients will be high and hospital formulary restrictions may reduce access.^[347](#fn347){ref-type="fn"}^ Medical diagnostics on the other hand are generally reimbursed according to Current Procedural Terminology codes managed by the American Medical Association, and the reimbursement rates established by the CMS.^[348](#fn348){ref-type="fn"}^ The existing reimbursement system has established codes with fixed rates for certain disease states that would need to be changed for all types of PM diagnostics to be reimbursed according to their value based on evidence.^[349](#fn349){ref-type="fn"}^ In addition, Medicare, the American government\'s largest health insurance plan, has declared that it will not pay for most preventative genetic testing.^[350](#fn350){ref-type="fn"}^ Under statute, CMS cannot reimburse for preventative services without Congressional approval. It is therefore unclear what evidence or reimbursement changes will spur additional coverage of CDx at the federal level.^[351](#fn351){ref-type="fn"}^

Recommendations for Reimbursement of PM {#sec3-14}
---------------------------------------

Realizing the potential of PM by overcoming reimbursement barriers requires the creation of closer working relationships and clearer communications between drug and device manufacturers, regulators, and reimbursement authorities earlier in the drug development process.^[352](#fn352){ref-type="fn"}^ This would ensure that manufacturers understand what kind of evidence is necessary for reimbursement decisions.^[353](#fn353){ref-type="fn"}^ While earlier involvement of reimbursement agencies requires a shift in traditional timelines, it would enable HTA and cost-effectiveness considerations to be incorporated earlier in the design of clinical programs.^[354](#fn354){ref-type="fn"}^ Increasing the predictability of reimbursement for PM products should facilitate the development of PM.^[355](#fn355){ref-type="fn"}^ Clarifying current reimbursement guidelines and the basis on which risk-benefit and effectiveness determinations are made would illuminate decision criteria and valuation interpretations,^[356](#fn356){ref-type="fn"}^ thereby facilitating business decisions and preparation for regulatory and reimbursement submissions.

Some articles recommend greater alignment between safety regulators and reimbursement authorities.^[357](#fn357){ref-type="fn"}^ In the USA, such alignment would broaden the remit of the FDA beyond safety and efficacy concerns to include considerations of comparative effectiveness and clinical utility. Numerous commentators consider this reform not as a wholesale change but as a novel approach to regulatory approvals specifically aimed at assessing PM drugs and their CDx. Many stakeholders believe that regulators and researchers should consider clinical utility and cost-effectiveness data in the development of drugs, biomarkers, and diagnostics.^[358](#fn358){ref-type="fn"}^

The creation of shared models of valuation between regulatory and reimbursement authorities, coupled with adoption of complementary evidentiary standards that include data on clinical utility,^[359](#fn359){ref-type="fn"}^ would facilitate a more predictable return on investment for PM developers. If regulators require effectiveness data to be generated in clinical trials, these data could create an evidence base for PM to satisfy reimbursement authorities. Pathways for these data to be passed on to hospitals, clinicians, and payers could further facilitate adoption of PM products. In addition, where complete effectiveness evidence is not available, conditional reimbursement could be granted contingent on generation of additional effectiveness evidence and ongoing CER.^[360](#fn360){ref-type="fn"}^ This would require alignment between conditional regulatory approvals and conditional reimbursement, both of which would be reliant on postmarket data collection. Reimbursement authorities might require submission of a strategy for how postmarket evidence will be generated prior to unconditional approval.^[361](#fn361){ref-type="fn"}^ Consequently, drug and device manufacturers need to develop standardized methods to assess validity and utility. This will provide data to reimbursement authorities in a standardized fashion.^[362](#fn362){ref-type="fn"}^ Developing and harmonizing clinical best practices and practices for modeling economic outcomes of PM will be an important part of this exercise.

Other recommendations advocate greater change to reimbursement policies, including a move away from cost-based reimbursement of diagnostics to value-based reimbursement.^[363](#fn363){ref-type="fn"}^ Focusing on value rather than on technology or process will create incentives for investment in CDx and move diagnostics onto a more level playing field with drug reimbursement.^[364](#fn364){ref-type="fn"}^ While this would certainly create incentives to invest in diagnostics, it is unclear what the overall impact of such a change would be on healthcare costs and resource allocation. Keeping costs under control in this scenario might involve federal price controls on patented tests and pharmaceuticals.^[365](#fn365){ref-type="fn"}^ Other systemic changes include changing the reimbursement codes that are used by clinicians, hospitals, and insurance companies to keep up with new advances in diagnostics.^[366](#fn366){ref-type="fn"}^ This would enable reimbursement of precision therapeutics and incentivize next-generation diagnostics that may be more cost-effective than standard treatments that do not segment the population. However, as whole genome sequencing increases in use for diagnosis, greater evidence of its analytic and clinical validity as well as clinical utility should be required.^[367](#fn367){ref-type="fn"}^ Finally, a number of authors underline the need for the HTA system to be changed to respond to PM.^[368](#fn368){ref-type="fn"}^ HTA needs to be adapted for the evaluation of combination products and those diagnostics aimed at smaller segments of the patient population.

CONCLUSION {#sec4}
==========

PM promises to be at the forefront of government and scientific agendas for the foreseeable future. Since beginning our research, the PMI has motivated significant US health research and policy action; there will be continued spending, development of infrastructure, and data-sharing systems. The FDA final guidance on LDTs is expected at any time. Revisions to the federal Common Rule will continue to be debated. The open reference platform of precision FDA will generate information that will help inform future regulatory directions and decision making. Pharmaceutical and biotechnology companies will continue to work toward developing personalized treatments and diagnostics, not just in the USA but around the globe.^[369](#fn369){ref-type="fn"}^ While the reviewed articles express concern about barriers to PM, they all assume that PM would bring tangible benefits to patients and/or healthcare systems (a limitation of our study).

Our research revealed the significant regulatory and non-regulatory barriers to the realization of PM, which will need to be addressed in tandem. In the first instance, while PM R&D has focused almost exclusively on genetics, it has become clear that genes are not as predictive as once believed. Indeed, highly prevalent and predictive genetic mutations are uncommon. Thus, the science of PM requires broadening to include fields such as proteomics, metabolomics, and cell therapies. In addition, there is a lack of clinical uptake of PM by healthcare providers resulting from both structural and human factors. The structural barriers include the traditional focus on treatment of disease rather than its prevention in the current US healthcare system.^[370](#fn370){ref-type="fn"}^ PM tests will require greater resources and expertise for interpretation and explanation of the meaning of test results for patients.^[371](#fn371){ref-type="fn"}^ Human factors include inadequate clinician education and/or training in PM, especially genetics, and, therefore, lack of expertise and comfort with interpretation of test results^[372](#fn372){ref-type="fn"}^ and how best to counsel patients. Lack of training inhibits clinical uptake, which, in turn, will impede the generation of data on clinical utility of PM products and services.

Addressing the structural, financial, and regulatory barriers to PM needs to proceed in lock-step with scientific advances if PM is to reach its promised potential. Indicators are that reforms will be propelled by the scientific community, industry, political will, and, most importantly, the patient advocacy community---the ultimate beneficiary of PM technologies and services.
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